8 recruiting, 8 unknown, 3 completed, 1 active not recruiting. 18 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Recruiting 7, Unknown 7, Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
Follow Sintilimab: new trials by email Literature Review of Sintilimab trials Research Report on Sintilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer Ipilimumab N01, Sintilimab, Cetuximab - BRAF V600E, Colorectal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 49 | 2026-03-01 | 2026-04-07 |
| Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma Thiotepa, Pirtobrutinib , Sintilimab(TPS) - Pirtobrutinib, Sintilimab | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 24 | 2026-02-10 | 2026-02-18 |
| Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma sintilimab combined with bevacizumab biosimilar - Hepatocellular Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Sun Yat-sen University | 37 | 2026-01-14 | 2026-01-16 |
| The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients Experimental - NSCLC, Sintilimab | Phase 2 | Recruiting | The Third Xiangya Hospital of Central South University | 35 | 2025-08-29 | 2026-09-02 |
| Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer SOX+Sintilimab, FLOT+Sintilimab - Neoadjuvant Chemotherapy, Sintilimab | Phase 2 | Not yet recruiting | Xijing Hospital | 200 | 2024-12-01 | 2024-10-10 |
| Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC Experimental, Active comparator - NSCLC, Neoadjuvant Immunotherapy | Phase 2 | Recruiting | Anhui Provincial Cancer Hospital | 86 | 2024-11-20 | 2025-02-10 |
| Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma Sintilimab - Esophageal Cancer, Chemoradiotherapy | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 191 | 2024-06-01 | 2024-07-16 |
| bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma bTAE-HAIC, Lenvatinib, Sintilimab - Liver Diseases, Hepatocellular Carcinoma | Not applicable | Unknown | Sun Yat-sen University | 30 | 2024-05-20 | 2024-08-09 |
| Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support - Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 57 | 2024-03-14 | 2026-10-07 |
| Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma Sintilimab (PD-1 Antibody) - Nasopharyngeal Carcinoma, Sintilimab | Recruiting | Cancer Hospital of Guangxi Medical University | 43 | 2022-07-30 | 2023-02-01 | |
| SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma sintilimab, Trastuzumab, S-1 plus oxaliplatin - HER2-positive, Locally Advanced Solid Tumor | Phase 2 | Unknown | Aiping Zhou | 44 | 2022-04-01 | 2022-04-06 |
| Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer Sintilimab, S-1, Oxaliplatin - Gastric Cancer, Perioperative | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 210 | 2021-06-21 | 2021-08-31 |
| A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer Sintilimab, Cisplatin, External Beam Radiotherapy (EBRT) - Uterine Cervical Neoplasms, Sintilimab | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2021-03-08 | 2021-12-28 |
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC Neoadjuvant therapy 1 - Sintilimab, Lung Cancer | Phase 2 | Active not recruiting | Tang-Du Hospital | 45 | 2021-03-01 | 2024-10-18 |
| HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT Hepatic arterial infusion chemotherapy, Lenvatinib, Sintilimab - Carcinoma, Hepatocellular, Liver Neoplasms | Not applicable | Completed | Sun Yat-sen University | 30 | 2021-01-01 | 2024-03-06 |
| Sintilimab in FH-deficient Renal Cell Carcinoma Sintilimab - Renal Cell Carcinoma, FH-deficient | Phase 2 | Unknown | West China Hospital | 37 | 2020-06-01 | 2020-05-12 |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) Anlotinib plus Sintilimab - Colorectal Cancer, Immunotherapy | Phase 2 | Completed | Shanghai Changzheng Hospital | 30 | 2020-06-01 | 2024-04-23 |
| Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. Sintilimab-R-CHOP - Diffuse Large B-Cell Lymphoma, Sintilimab | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 30 | 2019-12-01 | 2019-12-11 |
| SRS Sequential Sindilimab in Brain Metastasis of NSLSC SRS sequential sintilimab - NSCLC Stage IV, Brain Metastases | Phase 2 | Unknown | Xiaorong Dong | 25 | 2019-11-01 | 2019-11-27 |
| Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer sintilimab - Brain Metastases, Non Small Cell Lung Cancer | Phase 2 | Unknown | Sun Yat-sen University | 60 | 2019-04-29 | 2019-12-30 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (3) · Brain Neoplasms (2) · Colorectal Neoplasms (2) · Carcinoma, Renal Cell (1) · Esophageal Neoplasms (1) · Liver Diseases (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Nasopharyngeal Carcinoma (1) · Spinocerebellar Degenerations (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1)
Neoplasms (15) · Neoplasms by Site (14) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Neoplasms by Histologic Type (6) · Carcinoma (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Brain Diseases (3)
sintilimab (14) · anlotinib (3) · Antibodies (2) · Oxaliplatin (2) · S 1 (combination) (2) · lenvatinib (2) · Bevacizumab (1) · Brachytherapy (1) · Cetuximab (1) · Cisplatin (1) · Drug Therapy (1) · Immune Checkpoint Inhibitors (1) · Radiotherapy (1) · Thiotepa (1) · Trastuzumab (1)
Sun Yat-sen University (5) · Tianjin Medical University Cancer Institute and Hospital (2) · Zhejiang Cancer Hospital (2) · Aiping Zhou (1) · Anhui Provincial Cancer Hospital (1) · Cancer Hospital of Guangxi Medical University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese Academy of Medical Sciences (1) · Shanghai Changzheng Hospital (1) · Tang-Du Hospital (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The Third Xiangya Hospital of Central South University (1) · West China Hospital (1) · Xiaorong Dong (1) · Xijing Hospital (1)
China (18)
Haiyan Yang, MD (1) · Han Liang, PhD. (1) · Jianyang Wang, MD (1) · Jinhua Huang, Professor (1) · Kangshun Zhu, MD (1) · Likun Chen, doctor (1) · Ling Li, Master (1) · Longzhen Zhang, MD (1) · Xiao-Dong Zhu, Doctor (1) · Xuewei Ding, PhD. (1) · Yongling Ji (1) · Yuankai Shi, M.D (1) · Zhimei Hunag, MD (1) · Zhiming Li (1)